facebook button Trials
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Current Trials

Condition Name Sponsor
Solid Tumor or Lymphoma Zai Lab: ZL-1201-001 Zai Lab (Shanghai) Co., Ltd.
Various Indications [Sample Collection] Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022) MT Group
Non-Small Cell Lung Cancer LEAP-008: Second Line Lenvatinib and Pembrolizumab Merck Sharp & Dohme Corp.
Ovarian Cancer EP0057-201: A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with olaparib Ellipses Pharma
Multiple Myeloma [Registry] A Multi-Center, Randomized, Pilot Trial to Evaluate the My Hematology Oncocogy Patient Experience (MYHOPE) for Multiple Myelome (MM) Digital Care Network in Patients with MM (MyHOPE) Celgene Corporation
Non-Small Cell Lung Cancer Spectum: Poziotinib for EGFR/HER2 Exon 20 Mutated Non-Small Cell Lung Cancer Spectrum Pharmaceuticals, Inc.
Chemotherapy-Induced Oral Mucositis Chemo Mouthpiece Medical Device Trial Chemo Mouthpiece, LLC
Colon or Rectal Cancer LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash Lutris Pharma Ltd.
Non-small Cell Lung Cancer D9106C00001: Neoadjuvant/Adjuvant Durvalumab for Patients with Resectable Non-small Cell Lung Cancer AstraZeneca
Hyperkalemia/Chronic Kidney Disease NYH-01: Hyperkalemia/Chronic Kidney Disease Relypsa
Non-Small Cell Lung Cancer TROPION-Lung05: DS-1062a in NSCLC with actionable genetic mutations Daiichi Sankyo, Inc.
Non-Small Cell Lung Cancer Second Line Sitravatinib Plus Nivolumab Mirati Therapeutics, Inc.
Solid Tumors [Sample Collection] A Prospective Blood Sample Collection Study to Evaluate a Panel of Protein-based Biomarkers (SEERPRO) Seer, Inc.
Various Indications [Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx) Precision for Medicine
Oropharynx or Oral Cavity Cancer Galera ROMAN: GC4419 for Radiation Induced Oral Mucositis Galera Therapeutics, Inc.
Hematologic Malignancies KPG-818 for Patients with Hematologic Malignancies Kangpu Biopharmaceuticals, Ltd.
Solid Tumors MyTACTIC: Multiple Cohort Solid Tumor Trial Genentech, Inc.
Prostate Cancer KPG-121 in Castration Resistant Prostate Cancer Kangpu Biopharmaceuticals, Ltd.
Solid Tumors Clovis LODESTAR: Rucaparib in HRD Mutated Solid Tumors Clovis Oncology, Inc.
Non-Small Cell Lung Cancer Zeno: ZN-e4-001 Zeno Pharmaceuticals, Inc.
Various Indications [Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035) SERATRIALS, LLC.
Bone Metastasis CBD for Opioid Reduction VerdePharmHealth, LLC
Solid Tumors Merck KEYLYNK-007: Nivolumab plus Olaparib for Patients with HRR Mutated Solid Tumors Merck Sharp & Dohme Corp.
Pancreatic Cancer Ipsen Napoli: First Line Onivyde, Oxaliplatin, and 5-FU/Leucovorin Versus Gemcitabine and Nab-Paclitaxel Ipsen
Urothelial Carcinoma Basilea: Derzantinib for Patients with a Mutation in FGFR1-3 Basilea Pharmaceutica
Cutaneous Squamous Cell Carcinoma [Registry] CemiplimAb in Cutaneous Squamous Cell Carcinoma (CASE) Regeneron Pharmaceuticals, Inc.
Pancreatic Cancer Tyme-88-Panc: SM-88 as Third Line Therapy Tyme, Inc.
Ovarian Cancer AVB-S6-500 in Combination With Paclitaxel vs Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer Aravive, Inc.
Myelodysplatic Syndrome or Acute Myeloid Leukemia [Registry] An Observational Study to Collect and Assess Tissue Samples from Subjects With Documented Hematologic Malignancy (ANSWer) Notable Labs
Advanced or Metastatic Solid Tumors Exelixis: Cabozantinib plus Atezolizumab for Subjects with Locally Advanced or Metastatic Solid Tumors Exelixis
Solid Tumors OnTARGET: Crofelemer for Diarrhea Prophylaxis in Patients Receiving Targeted Therapy Napo Pharmaceuticals